ArticleFrontiers in oncology2026
Multiparametric MRI-based radiomics of whole-tumor and habitat regions for predicting HER2 status in young breast cancer: a two-center study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Habitat imaging can quantify intratumoral heterogeneity in young breast cancer patients, providing support for the prediction of HER2 expression levels. Therefore, this study aimed to compare the predictive ability of habitat models and conventional whole-tumor models for HER2 expression status in young breast cancer patients using multiparametric MRI. Methods: A retrospective cohort consisting of 375 young breast cancer patients (age < 40 years) who underwent preoperative MRI scanning at two medical centers was included in this study. Two binary classification tasks were designed: Task 1 (HER2 negative expression vs. HER2 positive expression) and Task 2 (HER2 zero expression vs. HER2 low expression). The training cohort (n=206) comprised patients from Center 1, with the external validation cohort (n=169) recruited from Center 2. Clinicopathological and MRI characteristics were collected. Radiomics features based on whole-tumor and habitat regions were extracted from DCE-MRI and DWI images, respectively. Clinical models, conventional whole-tumor models, habitat models, and combined models were constructed. Subsequently, model performance was evaluated by the AUC, sensitivity, and specificity. Results: In Task 1, the AUC of the clinical model, conventional whole-tumor model, habitat model, and combined model in the training cohort were 0.683, 0.731, 0.761, and 0.768 respectively. In Task 2, no clinicopathological features were determined as independent risk factors, thus no clinical model was developed. The AUC for the whole-tumor model, habitat model, and combined model in the training cohort were 0.673, 0.649, and 0.758 respectively. Conclusion: The habitat model exhibited better discriminatory effectiveness in identifying HER2 positive expression in young breast cancer patients, in comparison to the whole-tumor radiomics model. The integration of conventional whole-tumor radiomics features with habitat features and clinicopathological characteristics can enhance model performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.